Loading patent…
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsStanislav Svetlov, Ronald L. Hayes, Ka-Wang (Kevin) Wang
Estimating the term…
Traumatic insult to the brain leads to a degradation of low molecular weight of cannabinoid type 1 receptor (CB1) and generation of high molecular weight complexes in the cortex and hippocampus, as assessed by both N-terminal and C-terminal specific antibodies. The formation and release of CB1 oligomers was dramatically increased into CSF within 1 hour following traumatic brain insult. Novel CB1 receptor-based, prognostic markers of traumatic brain injury and other forms of brain injury are disclosed. A method of repopulating damaged neural cells by proliferation of a subgroup of neural progenitor cells is described. Targeting CB1 receptors for therapeutic neuroprotection in TBI is also disclosed.
A method for determining the presence of traumatic brain injury (TBI), comprising analyzing for cannabinoid receptor type 1 (CB1) extracellular N-terminal and C-terminal biomarker proteins selected from the group consisting of 40-42 kDa, 62-64 kDa, 120-130 kDa, and >260 kDa monomeric or multimeric CB1 complexes in a cerebral spinal fluid (CSF), hippocampal, cortical or serum sample from a subject suspected of having TBI within and up to about 14 days from the TBI;
Dependencies are inferred from the claim text.